Engineered T Cell Receptor for Cancer Immunotherapy
10.4062/biomolther.2023.197
- Author:
So Won LEE
1
;
Hyang-Mi LEE
Author Information
1. College of Pharmacy, Dongduk Women’s University, Seoul 02748, Republic of Korea
- Publication Type:Review
- From:Biomolecules & Therapeutics
2024;32(4):424-431
- CountryRepublic of Korea
- Language:EN
-
Abstract:
Among the therapeutic strategies in cancer immunotherapy—such as immune-modulating antibodies, cancer vaccines, or adoptive T cell transfer—T cells have been an attractive target due to their cytotoxicity toward tumor cells and the tumor antigen-specific binding of their receptors. Leveraging the unique properties of T cells, chimeric antigen receptor-T cells and T cell receptor (TCR)-T cells were developed through genetic modification of their receptors, enhancing the specificity and effectiveness of T cell therapy. Adoptive cell transfer of chimeric antigen receptor-T cells has been successful for the treatment of hematological malignancies. To expand T cell therapy to solid tumors, T cells are modified to express defined TCR targeting tumor associated antigen, which is called TCR-T therapy. This review discusses anti-tumor T cell therapies, with a focus on engineered TCR-T cell therapy.We outline the characteristics of TCR-T cell therapy and its clinical application to non-hematological malignancies.
